| Name | AB-CHMINACA |
|---|
| Formal Name | N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1- (cyclohexylmethyl)- 1H-indazole-3-carboxamide |
|---|
| SMILES | O=C(N[C@H](C(N)=O)C(C)C)C1=NN(CC2CCCCC2)C3=C1C=CC=C3 |
|---|
| InChI Key | KJNZIEGLNLCWTQ-KRWDZBQOSA-N |
|---|
| InChI Code | InChI=1S/C20H28N4O2/c1-13(2)17(19(21)25)22-20(26)18-15-10-6-7-11-16(15)24(23-18)12-14-8- 4-3-5-9-14/h6-7,10-11,13-14,17H,3-5,8-9,12H2,1-2H3,(H2,21,25)(H,22,26)/t17-/m0/s1 |
|---|
| Description | AB-CHMINACA is a cannabinoid receptor modulator that was first synthesized by Pfizer for its potential therapeutic use. The Ki toward the CB1 receptor was reported in a 2009 patent to be 0.5 nM.1 AB-CHMINACA is one of many new designer drugs being detected in illegal spice/herbal products. AB-CHMINACA is structurally related to another Pfizer cannabinoid, AB-FUBINACA, in that the p-fluorophenyl group has been replaced with a cyclohexyl group. AB-FUBINACA is a similarly potent CB1 receptor modulator that is now a US DEA regulated Schedule I controlled substance (Drug Code 7012) after having been identified in illegal products. |
|---|
Status |
Verified |
|---|
| Submitted | 2014-06-01 |
|---|
| Submitted By | Cayman Chemical
Kentucky State Police Eastern Laboratory Branch, Ashland, KY |
|---|
| Published | 2014-07-22 |
|---|
| Contact | Paul D. Kennedy, PhD. at Cayman Chemical |
|---|
| Product Details | Link |
|---|
Monograph |
Download the AB-CHMINACA Monograph |
|---|
|
|
